Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $30 | ― | 4.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $31 | ― | 5.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $33 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $59 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $62 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $41 | ― | 4.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $25 | ― | 4.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $6 | ― | 4.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $22 | ― | 4.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY ― | ― | 10.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $22→$8 | ― | 10.00% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $210 | ― | 7.10% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $19 | ― | 10.30% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $7 | ― | 12.00% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $220→$350 | ― | 40.60% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $130 | ― | 24.90% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $40 | ― | 8.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $125→$127 | ― | 19.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $64.3 | ― | 6.50% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $15 | ― | 6.90% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $220→$205 | ― | 7.70% | Reiterated | ||||
| Repligen | BUY $160 | ― | -6.00% | Initiated | Repligen initiated with a Buy at Rothschild & Co Redburn | |||
| Resmed | BUY ― | ― | -3.60% | Reiterated | ResMed: Buy Rating on Depressed Valuation as Market Overprices Philips and GLP‑1 Risks | |||
 | BP | BUY $38.5→$57 | ― | -4.20% | Upgraded | BP upgraded to Outperform from Neutral at BNP Paribas | |||
| Exxon Mobil | HOLD $125→$165 | ― | -4.20% | Upgraded | Exxon Mobil upgraded to Neutral from Underperform at BNP Paribas | |||
| Shell | HOLD $101 | ― | -4.20% | Downgraded | Shell downgraded to Neutral from Outperform at BNP Paribas | |||
| Chevron | BUY ― | ― | -4.20% | Upgraded | Chevron upgraded to Outperform from Neutral at BNP Paribas | |||
Herman Zahl ParetoNot Ranked | Gjensidige Forsikring | BUY ― | ― | ― | Upgraded | Gjensidige upgraded to Buy from Hold at Pareto | |||
 | Clorox | SELL $117→$99 | ― | -1.00% | Downgraded | Clorox downgraded to Underweight from Neutral at JPMorgan | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $28 | ― | 28.90% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $110→$53 | ― | 20.50% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $51→$48 | ― | 7.50% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $26→$41 | ― | 20.50% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50 | ― | 24.90% | Assigned | ||||
| Abbott Laboratories | BUY ― | ― | -3.60% | Reiterated | Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and BioAge Labs, Inc. (NASDAQ: BIOA) | |||
 | ServiceTitan, Inc. Class A | BUY $100 | ― | -9.20% | Assigned | ServiceTitan: Expanding Market Leadership and Product Momentum Support Buy Rating | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY ― | ― | 5.40% | Reiterated | ||||
 | Sutro Biopharma | BUY $23→$35 | ― | -9.00% | Reiterated | Sutro Biopharma price target raised to $35 from $23 at Citizens | |||
| Pitney Bowes | BUY $13→$14 | ― | -0.90% | Reiterated | Pitney Bowes price target raised to $14 from $13 at Citizens | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $105→$85 | ― | 15.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $16→$15 | ― | 15.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $120 | ― | 9.00% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $30.5 | ― | 5.30% | Reiterated | ||||
| Sarepta Therapeutics | BUY $35 | ― | -7.40% | Reiterated | Analysts Are Bullish on Top Healthcare Stocks: Evommune, Inc. (EVMN), Sarepta Therapeutics (SRPT) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $185 | ― | 40.60% | Downgraded | ||||
 | Duos Technologies Group | BUY $14→$17 | ― | -15.90% | Reiterated | Duos Technologies price target raised to $17 from $14 at Ascendiant | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $14 | ― | 4.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $225 | ― | 3.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50 | ― | 14.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $15 | ― | 4.20% | Reiterated |
Rows:
